Search results for "Autologous transplantation"

showing 8 items of 18 documents

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature res…

2014

Summary Salvage therapy followed by high-dose therapy (HDT) remains a mainstay for patients with relapsed lymphoma, however no optimal regimen has been defined. Here we report on the results of R-DexaBEAM (rituximab, dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by HDT. Patients aged 18–65 years, Eastern Cooperative Oncology Group performance score 0–2, with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) were eligible. R-Dexa-BEAM was given for two cycles followed by stem cell mobilization and HDT. Primary endpoint of the trial was progression-free-survival (PFS). One hundred and three patients were included: aggressive NHL (aNHL): diffuse large B-cell lymphom…

OncologyMelphalanAdultMalemedicine.medical_specialtyLymphoma B-CellFollicular lymphomaSalvage therapyKaplan-Meier EstimateDexamethasoneDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedYoung Adultimmune system diseasesRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAutologous transplantationHumansProspective StudiesMelphalanEtoposideAgedEtoposideSalvage TherapyDose-Response Relationship Drugbusiness.industryPatient SelectionRemission InductionCytarabineHematologyMiddle Agedmedicine.diseaseCarmustineHematopoietic Stem Cell MobilizationLymphomaSurgeryMantle cell lymphomaRituximabFemalebusinessRituximabmedicine.drugBritish journal of haematology
researchProduct

The role of stem cell transplantation in follicular lymphoma.

2017

With the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is dominantly used in patients with a highrisk profile, e.g. failure of response, early or multiply relapse and/or signs of transformation. The ideal place for allogeneic transplantation is even harder to define, …

Oncologymedicine.medical_specialtyAllogeneic transplantationSide effectClinical BiochemistryFollicular lymphomaTransplantation Autologous03 medical and health sciences0302 clinical medicineInternal medicinemedicineAutologous transplantationHumansIn patientPrecision MedicineLymphoma Follicularbusiness.industryHematopoietic Stem Cell Transplantationmedicine.diseaseTransplantationOncology030220 oncology & carcinogenesisRituximabStem cellbusinessRituximab030215 immunologymedicine.drugBest practiceresearch. Clinical haematology
researchProduct

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results f…

2021

Abstract Background: Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German-speaking Myeloma Multicenter Group (GMMG HD6) investigated the addition of the anti-SLAMF7 moAb elotuzumab to lenalidomide / bortezomib / dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible NDMM. Patients and Methods: Patients were equally randomized into four treatment arms, stratified by International Staging System (ISS). Treatment consisted of four 21-da…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyNewly diagnosedmedicine.diseaseBiochemistryInternal medicineMedicineAutologous transplantationElotuzumabbusinessMultiple myelomaBortezomib/dexamethasonemedicine.drugLenalidomideBlood
researchProduct

Adipose tissue sensitivity to radiation exposure

2008

1525-2191 (Electronic) Journal Article Research Support, Non-U.S. Gov't; Treatment of cancer using radiation can be significantly compromised by the development of severe acute and late damage to normal tissue. Treatments that either reduce the risk and severity of damage or that facilitate the healing of radiation injuries are being developed, including autologous adipose tissue grafts to repair tissue defects or involutional disorders that result from tumor resection. Adipose tissue is specialized in energy storage and contains different cell types, including preadipocytes, which could be used for autologous transplantation. It has long been considered a poorly proliferative connective ti…

Pathologymedicine.medical_specialtyCellular differentiationPopulationExperimental/metabolism/*pathologyAdipose tissueConnective tissueCell Proliferation/*radiation effectsBiologyPolymerase Chain ReactionPathology and Forensic MedicineMiceOxidative Stress/radiation effectsmedicineAdipocytesIn Situ Nick-End LabelingAutologous transplantationAnimalsStem Cells/metabolism/pathology/radiation effectsProgenitor celleducationRadiation InjuriesCell Proliferationeducation.field_of_studyStem CellsAdipocytes/cytology/metabolism/*radiation effectsCell DifferentiationTotal body irradiationFlow CytometryImmunohistochemistryAdipose Tissue/cytology/*radiation effectsOxidative StressRadiation Injuries ExperimentalCell Differentiation/*radiation effectsmedicine.anatomical_structurePhenotypeAdipose TissueStem cellRegular Articles
researchProduct

Cambios en el estado nutricional, composición corporal y sintomatología asociada en pacientes hospitalizados sometidos a trasplante de médula ósea: e…

2021

Introducción: Los pacientes sometidos a Trasplante de Células Madre Hematopoyéticas o trasplante de médula padecen varias complicaciones nutricionales. El objetivo del estudio fue realizar una descripción prospectiva en estos pacientes.Material y métodos: Se reclutaron 14 pacientes con una edad media de 48,0±9,8 años. Resultados: El 28,6% padecía sobrepeso, el 14,3% obesidad y el 57,1% tenía un peso normal, con una evoluciónentre -0,3±0,3 kg/m2 (normopeso) hasta -3,1±0,2 kg/m2 (obesidad). Se observó una pérdida de peso variable, de hasta 7,3±0,7% en pacientes con mayor Índice de Masa Corporal (IMC). La composición corporal también empeoró al alta, con una evolución de la circunferencia braq…

Trasplante de Médula Óseamedicine.medical_specialtyRC620-627Allogeneic transplantationNauseaTrasplantació d'òrgans teixits etc.OverweightGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineMedicineAutologous transplantationTX341-641PacientsComposición CorporalNutritional diseases. Deficiency diseasesEstado NutricionalNutrition and DieteticsNutrition. Foods and food supplybusiness.industryEfectos secundariosmedicine.diseaseObesityDysgeusia030220 oncology & carcinogenesisTrastorns de la nutricióVomitingmedicine.symptombusinessBody mass index030215 immunologyFood Science
researchProduct

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is…

2006

BACKGROUND AND OBJECTIVES: This European Group for Blood and Marrow Transplantation (EBMT) multicentre randomized phase III study was designed to assess the safety and efficacy of CD34+ selection in newly diagnosed myeloma patients undergoing autologous transplantation. DESIGN AND METHODS: One hundred and eleven patients responsive to initial chemotherapy were randomized to receive CD34+ selected (arm A) or unselected PBPC (arm B) after conditioning with high-dose melphalan and TBI. ASO-PCR was used to assess purging efficacy and reinfused tumor load. Tumor load could be assessed in 59 patients. RESULTS: CD34+ selection gave a median tumor cell depletion of 2.2 logs (0.77-5.96). No tumor ce…

autologous transplantMelphalanOncologyAdultMaleRiskmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentAntigens CD34Transplantation AutologousDexamethasoneDisease-Free SurvivalPostoperative ComplicationsRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineEuropean Group for Blood and Marrow TransplantatioAutologous transplantationHumansSurvival rateSurvival analysisMultiple myelomaAgedChemotherapyPeripheral Blood Stem Cell TransplantationHematologybusiness.industryBone Marrow PurgingHematologyCD34+ selectionMiddle Agedmedicine.diseasePrognosisSurvival AnalysisBone marrow purgingSurgerySurvival RateTreatment OutcomeDoxorubicinVincristineFemalebusinessMultiple Myelomamedicine.drugFollow-Up StudiesHaematologica
researchProduct

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Beha…

2016

Abstract Background. Peripheral blood stem cell (PBSC) collection prior to high dose chemotherapy for autologous transplantation (ASCT) is a standard of care, and an attractive alternative to the use of bone marrow cells, for transplantation in Multiple Myeloma (MM). The optimal methodology for mobilizing PBSC has yet to be defined, both G-CSF and GM-CSF can be used; although, the stimulatory effect may be more pronounced when given after high dose cyclophosphamide (usually administered at a dose of 1.5 to 6g/m2 IV for one to two days) and use of Plerixafor, a CXCR4 antagonist (Mozobil®). The latter 2 options are preferred, overall, in France. Indeed, it was shown that the most recent combi…

medicine.medical_specialtyMobilizationbusiness.industryPlerixaforImmunologyCell BiologyHematologymedicine.diseaseBiochemistrySurgeryTransplantationHigh dose chemotherapyHigh dose cyclophosphamidemedicineAutologous transplantationIntensive care medicinebusinessMultiple myelomaHematopoietic Stem Cell Mobilizationmedicine.drugBlood
researchProduct

Uterus transplantation in a non-human primate: long-term follow-up after autologous transplantation

2012

BACKGROUND Uterus transplantation (UTx) may provide the first available treatment for women affected by uterine infertility. The present study aimed to further develop a surgical technique for autologous UTx in a non-human primate species and to assess long-term function. METHODS Female baboons (n= 16) underwent autologous transplantation of the uterus with the Fallopian tubes and ovaries, performed with a previously published surgical technique (n= 6, Group 1) or using a modified technique (n= 10; Group 2). The uterine arteries were dissected to the proximal end of the anterior branch (Group 1) or the entire (Group 2) internal iliac artery, and the ovarian veins were dissected to the cross…

medicine.medical_specialtyUterusOvaryBreedingIliac ArteryTransplantation AutologousVeinsUreterPregnancymedicine.arteryUterus transplantationmedicineAnimalsAutologous transplantationFallopian TubesPregnancybusiness.industryOvaryUterusRehabilitationObstetrics and GynecologyArteriesmedicine.diseaseInternal iliac arteryMenstruationSurgeryTreatment Outcomemedicine.anatomical_structureReproductive MedicineFemaleRenal veinbusinessFollow-Up StudiesPapioHuman Reproduction
researchProduct